The Longevity Fund

The Longevity Fund investment thesis

While it’s critical for new talent to understand and recruit the most talented drug developers in the industry, traditional company-building and fundraising strategies do not obviously translate. You need to think differently to build these companies. Longevity companies will involve fundamentally new regulatory, scientific, fundraising and company-building traits. Regulatory strategies to get lifespan drugs to market don't already exist, the science specific to longevity (from how you measure aging to accumulated knowledge of which interventions are BS) isn't common knowledge in the same way core principles of neurodegenerative disease and cancer are, fundraising looks completely different when you're raising for something conventional biotech VCs don't yet understand, and the types of en

The Longevity Fund team (2)

Partners and principals at The Longevity Fund:

• Laura Deming — sweet spot $500K
• Celine Haliqua — sweet spot $500K

The Longevity Fund portfolio companies

Companies listed on The Longevity Fund's public materials include: LETTER, PORTFOLIO, ABOUT, NEXT (age1).

Is The Longevity Fund a fit for your round?

Upload your pitch deck and see whether anyone at The Longevity Fund appears in your top matches.